
Bayer Aktiengesellschaft
BAYN.DE
Updated: 24/09/2026, 10:36:19
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.
No summaries found.
- Share price
- €49.00
- Market cap
- €48.14B
- Exchange
- XETRA
- Currency
- EUR
- CEO
- Bill Anderson
- Employees
- 87,830
- IPO date
- 16/12/1996
- Beta
- 0.834
- Last dividend
- €0.00
- Day range
- €49.00 – €49.74
- 52-week range
- €25.78 – €53.92
- 1-day performance
- -0.63%
- 1-year performance
- 90.07%
- Current drawdown (1Y)
- -9.12%
- CIK
- N/A
- CUSIP
- D0712D163
- ISIN
- DE000BAY0017
- Created
- 07/09/2026, 05:15:17
- Last update
- 24/09/2026, 10:36:19
Track Bayer Aktiengesellschaft with an AI analyst
See which prediction-market events move BAYN.DE, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.